Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evinacumab in Homozygous Familial Hypercholesterolemia (ELIPSE HoFH)
NCT03399786Phase 3Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Jan 2018
- Primary completion
- Jun 2019
- Modality
- Monoclonal Antibodies
- Countries
- 11
01
Overview
A Phase 3 trial of evinacumab in homozygous familial hypercholesterolemia (HoFH), sponsored by Regeneron Pharmaceuticals. Started Jan 2018; status: completed.
02
Drugs
evinacumab
03
Conditions
homozygous familial hypercholesterolemia (HoFH)
Beyond the preview
Go deeper on NCT03399786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03399786.